Skip to main content
NCBI home page
Sarcoma logoLink to Sarcoma
. 2003 Jun;7(2):43–55. doi: 10.1080/13577140310001607266

Management of Advanced Adult Soft Tissue Sarcoma

Vivien H C Bramwell 1,✉
PMCID: PMC2395519  PMID: 18521368

Full Text

The Full Text of this article is available as a PDF (117.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman K., Crowley J., Balcerzak S. P., Rivkin S. E., Weiss G. R., Elias A., Natale R. B., Cooper R. M., Barlogie B., Trump D. L. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993 Jul;11(7):1276–1285. doi: 10.1200/JCO.1993.11.7.1276. [DOI] [PubMed] [Google Scholar]
  2. Ballo M. T., Zagars G. K., Pollack A., Pisters P. W., Pollack R. A. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol. 1999 Jan;17(1):158–167. doi: 10.1200/JCO.1999.17.1.158. [DOI] [PubMed] [Google Scholar]
  3. Benjamin R. S. Grade 3 nausea, vomiting, and myelosuppression or progressive, metastatic sarcoma? J Clin Oncol. 1987 Jun;5(6):833–835. doi: 10.1200/JCO.1987.5.6.833. [DOI] [PubMed] [Google Scholar]
  4. Benjamin R. S., Rouëssé J., Bourgeois H., van Hoesel Q. G. Should patients with advanced sarcomas be treated with chemotherapy? . Eur J Cancer. 1998 Jun;34(7):958–965. doi: 10.1016/s0959-8049(98)00014-8. [DOI] [PubMed] [Google Scholar]
  5. Billingsley K. G., Lewis J. J., Leung D. H., Casper E. S., Woodruff J. M., Brennan M. F. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999 Jan 15;85(2):389–395. [PubMed] [Google Scholar]
  6. Bindal R. K., Sawaya R. E., Leavens M. E., Taylor S. H., Guinee V. F. Sarcoma metastatic to the brain: results of surgical treatment. Neurosurgery. 1994 Aug;35(2):185–191. doi: 10.1227/00006123-199408000-00002. [DOI] [PubMed] [Google Scholar]
  7. Blay J-Y, van Glabbeke M., Verweij J., van Oosterom A. T., Le Cesne A., Oosterhuis J. W., Judson I., Nielsen O. S. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer. 2003 Jan;39(1):64–69. doi: 10.1016/s0959-8049(02)00480-x. [DOI] [PubMed] [Google Scholar]
  8. Blay J. Y., Bouhour D., Ray-Coquard I., Dumontet C., Philip T., Biron P. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. J Clin Oncol. 2000 Nov 1;18(21):3643–3650. doi: 10.1200/JCO.2000.18.21.3643. [DOI] [PubMed] [Google Scholar]
  9. Bokemeyer C., Franzke A., Hartmann J. T., Schöber C., Arseniev L., Metzner B., Link H., Kanz L., Schmoll H. J. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer. 1997 Oct 1;80(7):1221–1227. [PubMed] [Google Scholar]
  10. Bramwell V. H., Anderson D., Charette M. L. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4(3):103–112. doi: 10.1080/13577140020008066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Bramwell Vivien H. C., Morris Donald, Ernst D. Scott, Hings Ingrid, Blackstein Martin, Venner Peter M., Ette Ene I., Harding Matthew W., Waxman Allison, Demetri George D. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma. Clin Cancer Res. 2002 Feb;8(2):383–393. [PubMed] [Google Scholar]
  12. Buesa J. M., López-Pousa A., Martín J., Antón A., García del Muro J., Bellmunt J., Arranz F., Valentí V., Escudero P., Menéndez D. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) Ann Oncol. 1998 Aug;9(8):871–876. doi: 10.1023/a:1008474802882. [DOI] [PubMed] [Google Scholar]
  13. Canellos G. P., Demetri G. D. Myelosuppression and "conventional" chemotherapy: what price, what benefit? J Clin Oncol. 1993 Jan;11(1):1–2. doi: 10.1200/JCO.1993.11.1.1. [DOI] [PubMed] [Google Scholar]
  14. Chauvel P. Osteosarcomas and adult soft tissue sarcomas: is there a place for high LET radiation therapy? Ann Oncol. 1992 Apr;3 (Suppl 2):S107–S110. doi: 10.1093/annonc/3.suppl_2.s107. [DOI] [PubMed] [Google Scholar]
  15. Coindre J. M., Terrier P., Guillou L., Le Doussal V., Collin F., Ranchère D., Sastre X., Vilain M. O., Bonichon F., N'Guyen Bui B. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer. 2001 May 15;91(10):1914–1926. doi: 10.1002/1097-0142(20010515)91:10<1914::aid-cncr1214>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  16. Colvin O. M. Drug resistance in the treatment of sarcomas. Semin Oncol. 1997 Oct;24(5):580–591. [PubMed] [Google Scholar]
  17. Crawley C. R., Judson I. R., Verrill M., Hill C., Raynaud F. I. A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma. Sarcoma. 1997;1(3-4):149–154. doi: 10.1080/13577149778236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. De Pas T., Curigliano G., Masci G., Catania C., Comandone A., Boni C., Tucci A., Pagani O., Marrocco E., de Braud F. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. Ann Oncol. 2002 Jan;13(1):161–166. doi: 10.1093/annonc/mdf004. [DOI] [PubMed] [Google Scholar]
  19. De Pas T., De Braud F., Orlando L., Nolè F., Munzone E., Zampino M. G., Fazio N., Aapro M. S., Goldhirsch A. High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol. 1998 Aug;9(8):917–919. doi: 10.1023/a:1008311901856. [DOI] [PubMed] [Google Scholar]
  20. DeMatteo R. P., Lewis J. J., Leung D., Mudan S. S., Woodruff J. M., Brennan M. F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000 Jan;231(1):51–58. doi: 10.1097/00000658-200001000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Demetri G. D., Elias A. D. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am. 1995 Aug;9(4):765–785. [PubMed] [Google Scholar]
  22. Demetri G. D., Fletcher C. D., Mueller E., Sarraf P., Naujoks R., Campbell N., Spiegelman B. M., Singer S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951–3956. doi: 10.1073/pnas.96.7.3951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Demetri George D. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs. 2002 May;13 (Suppl 1):S7–S9. [PubMed] [Google Scholar]
  24. Demetri George D., von Mehren Margaret, Blanke Charles D., Van den Abbeele Annick D., Eisenberg Burton, Roberts Peter J., Heinrich Michael C., Tuveson David A., Singer Samuel, Janicek Milos. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002 Aug 15;347(7):472–480. doi: 10.1056/NEJMoa020461. [DOI] [PubMed] [Google Scholar]
  25. Dumontet C., Biron P., Bouffet E., Blay J. Y., Meckenstock R., Chauvin F., Philip I., Clavel M., Brunat-Mentigny M., Philip T. High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. Bone Marrow Transplant. 1992 Nov;10(5):405–408. [PubMed] [Google Scholar]
  26. Edmonson J. H., Buckner J. C., Long H. J., Loprinzi C. L., Schaid D. J. Phase II study of ifosfamide-etoposide-mesna in adults with advanced nonosseous sarcomas. J Natl Cancer Inst. 1989 Jun 7;81(11):863–866. doi: 10.1093/jnci/81.11.863. [DOI] [PubMed] [Google Scholar]
  27. Edmonson J. H. Needed: qualitative improvement in antisarcoma therapy. J Clin Oncol. 1995 Jul;13(7):1531–1533. doi: 10.1200/JCO.1995.13.7.1531. [DOI] [PubMed] [Google Scholar]
  28. Edmonson J. H., Ryan L. M., Blum R. H., Brooks J. S., Shiraki M., Frytak S., Parkinson D. R. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993 Jul;11(7):1269–1275. doi: 10.1200/JCO.1993.11.7.1269. [DOI] [PubMed] [Google Scholar]
  29. Eilber F. C., Rosen G., Forscher C., Nelson S. D., Dorey F. J., Eilber F. R. Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol. 1999 Oct-Nov;6(7):645–650. doi: 10.1007/s10434-999-0645-8. [DOI] [PubMed] [Google Scholar]
  30. Esnaola N. F., Rubin B. P., Baldini E. H., Vasudevan N., Demetri G. D., Fletcher C. D., Singer S. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Ann Surg. 2001 Aug;234(2):215–223. doi: 10.1097/00000658-200108000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. España P., Chang P., Wiernik P. H. Increased incidence of brain metastases in sarcoma patients. Cancer. 1980 Jan 15;45(2):377–380. doi: 10.1002/1097-0142(19800115)45:2<377::aid-cncr2820450231>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  32. Fong Y., Coit D. G., Woodruff J. M., Brennan M. F. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg. 1993 Jan;217(1):72–77. doi: 10.1097/00000658-199301000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Frost D. B. Pulmonary metastasectomy for soft tissue sarcomas: is it justified? J Surg Oncol. 1995 Jun;59(2):110–115. doi: 10.1002/jso.2930590208. [DOI] [PubMed] [Google Scholar]
  34. Frustaci S., Buonadonna A., Galligioni E., Favaro D., De Paoli A., Lo Re G., Sorio R., Tumolo S., Monfardini S. Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study. J Clin Oncol. 1997 Apr;15(4):1418–1426. doi: 10.1200/JCO.1997.15.4.1418. [DOI] [PubMed] [Google Scholar]
  35. Frustaci S., Buonadonna A., Romanini A., Comandone A., Dalla Palma M., Gamucci T., Verusio C., Lionetto R., Dani C., Casali P. Increasing dose of continuous infusion ifosfamide and fixed dose of bolus epirubicin in soft tissue sarcomas. A study of the Italian group on rare tumors. Tumori. 1999 Jul-Aug;85(4):229–233. doi: 10.1177/030089169908500403. [DOI] [PubMed] [Google Scholar]
  36. Goss G., Demetri G. Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surg Oncol. 2000 Aug;9(2):53–59. doi: 10.1016/s0960-7404(00)00023-2. [DOI] [PubMed] [Google Scholar]
  37. Gunderson L. L., Nagorney D. M., McIlrath D. C., Fieck J. M., Wieand H. S., Martinez A., Pritchard D. J., Sim F., Martenson J. A., Edmonson J. H. External beam and intraoperative electron irradiation for locally advanced soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):647–656. doi: 10.1016/0360-3016(93)90011-j. [DOI] [PubMed] [Google Scholar]
  38. Hamilton L., Blackstein M., Berk T., McLeod R. S., Gallinger S., Madlensky L., Cohen Z. Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases. Can J Surg. 1996 Jun;39(3):247–252. [PMC free article] [PubMed] [Google Scholar]
  39. Harrison L. E., Brennan M. F., Newman E., Fortner J. G., Picardo A., Blumgart L. H., Fong Y. Hepatic resection for noncolorectal, nonneuroendocrine metastases: a fifteen-year experience with ninety-six patients. Surgery. 1997 Jun;121(6):625–632. doi: 10.1016/s0039-6060(97)90050-7. [DOI] [PubMed] [Google Scholar]
  40. Heymach J. V. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol. 2001 Jul;13(4):261–269. doi: 10.1097/00001622-200107000-00009. [DOI] [PubMed] [Google Scholar]
  41. Hicks L. G., Balcerzak S. P., Zalupski M. GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study. Cancer Invest. 1996;14(6):507–512. doi: 10.3109/07357909609076895. [DOI] [PubMed] [Google Scholar]
  42. Judson I., Radford J. A., Harris M., Blay J. Y., van Hoesel Q., le Cesne A., van Oosterom A. T., Clemons M. J., Kamby C., Hermans C. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001 May;37(7):870–877. doi: 10.1016/s0959-8049(01)00050-8. [DOI] [PubMed] [Google Scholar]
  43. Karakousis C. P., Blumenson L. E., Canavese G., Rao U. Surgery for disseminated abdominal sarcoma. Am J Surg. 1992 Jun;163(6):560–564. doi: 10.1016/0002-9610(92)90556-7. [DOI] [PubMed] [Google Scholar]
  44. Keizer H. J., Crowther D., Nielsen O. S., Oosterom A. T., Muguiro J. H., Pottelberghe C. V., Somers R., Tursz T. EORTC Group Phase II Study of Oral Etoposide for Pretreated Soft Tissue Sarcoma. Sarcoma. 1997;1(2):99–101. doi: 10.1080/13577149778371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Keohan M. L., Taub R. N. Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol. 1997 Oct;24(5):572–579. [PubMed] [Google Scholar]
  46. Kindblom L. G., Remotti H. E., Aldenborg F., Meis-Kindblom J. M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998 May;152(5):1259–1269. [PMC free article] [PubMed] [Google Scholar]
  47. Lawrence W., Jr, Donegan W. L., Natarajan N., Mettlin C., Beart R., Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987 Apr;205(4):349–359. doi: 10.1097/00000658-198704000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Le Cesne A., Antoine E., Spielmann M., Le Chevalier T., Brain E., Toussaint C., Janin N., Kayitalire L., Fontaine F., Genin J. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995 Jul;13(7):1600–1608. doi: 10.1200/JCO.1995.13.7.1600. [DOI] [PubMed] [Google Scholar]
  49. Le Cesne A., Judson I., Crowther D., Rodenhuis S., Keizer H. J., Van Hoesel Q., Blay J. Y., Frisch J., Van Glabbeke M., Hermans C. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000 Jul;18(14):2676–2684. doi: 10.1200/JCO.2000.18.14.2676. [DOI] [PubMed] [Google Scholar]
  50. Leyvraz S., Bacchi M., Cerny T., Lissoni A., Sessa C., Bressoud A., Hermann R. Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol. 1998 Aug;9(8):877–884. doi: 10.1023/a:1008464504583. [DOI] [PubMed] [Google Scholar]
  51. Lopez M., Vici P., Di Lauro K., Conti F., Paoletti G., Ferraironi A., Sciuto R., Giannarelli D., Maini C. L. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol. 1998 Jan;16(1):86–92. doi: 10.1200/JCO.1998.16.1.86. [DOI] [PubMed] [Google Scholar]
  52. Mace Joseph, Sybil Biermann J., Sondak Vernon, McGinn Cornelius, Hayes Curtis, Thomas Dafydd, Baker Laurence. Response of extraabdominal desmoid tumors to therapy with imatinib mesylate. Cancer. 2002 Dec 1;95(11):2373–2379. doi: 10.1002/cncr.11029. [DOI] [PubMed] [Google Scholar]
  53. Maki R. G. Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol. 2001 Jul;13(4):270–274. doi: 10.1097/00001622-200107000-00010. [DOI] [PubMed] [Google Scholar]
  54. Mavligit G. M., Zukwiski A. A., Ellis L. M., Chuang V. P., Wallace S. Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer. 1995 Apr 15;75(8):2083–2088. doi: 10.1002/1097-0142(19950415)75:8<2083::aid-cncr2820750809>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  55. Mazeron J. J., Suit H. D. Lymph nodes as sites of metastases from sarcomas of soft tissue. Cancer. 1987 Oct 15;60(8):1800–1808. doi: 10.1002/1097-0142(19871015)60:8<1800::aid-cncr2820600822>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  56. Miettinen M., Sarlomo-Rikala M., Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology. Hum Pathol. 1999 Oct;30(10):1213–1220. doi: 10.1016/s0046-8177(99)90040-0. [DOI] [PubMed] [Google Scholar]
  57. Miser J. S., Kinsella T. J., Triche T. J., Tsokos M., Jarosinski P., Forquer R., Wesley R., Magrath I. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987 Aug;5(8):1191–1198. doi: 10.1200/JCO.1987.5.8.1191. [DOI] [PubMed] [Google Scholar]
  58. Mitchell G., Thomas J. M., Harmer C. L. Aggressive fibromatosis: evidence for a stable phase. Sarcoma. 1998;2(3-4):149–154. doi: 10.1080/13577149877902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Ng E. H., Pollock R. E., Romsdahl M. M. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992 Mar 15;69(6):1334–1341. doi: 10.1002/1097-0142(19920315)69:6<1334::aid-cncr2820690606>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  60. Nielsen O. S., Judson I., van Hoesel Q., le Cesne A., Keizer H. J., Blay J. Y., van Oosterom A., Radford J. A., Svancárová L., Krzemienlecki K. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2000 Jan;36(1):61–67. doi: 10.1016/s0959-8049(99)00240-3. [DOI] [PubMed] [Google Scholar]
  61. Nori D., Schupak K., Shiu M. H., Brennan M. F., Shupak K. Role of brachytherapy in recurrent extremity sarcoma in patients treated with prior surgery and irradiation. Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1229–1233. doi: 10.1016/0360-3016(91)90232-s. [DOI] [PubMed] [Google Scholar]
  62. Palumbo R., Neumaier C., Cosso M., Bertero G., Raffo P., Spadini N., Valente S., Villani G., Pastorino M., Toma S. Dose-intensive first-line chemotherapy with epirubicin and continuous infusion ifosfamide in adult patients with advanced soft tissue sarcomas: a phase II study. Eur J Cancer. 1999 Jan;35(1):66–72. doi: 10.1016/s0959-8049(98)00293-7. [DOI] [PubMed] [Google Scholar]
  63. Patel S. R., Vadhan-Raj S., Burgess M. A., Plager C., Papadopolous N., Jenkins J., Benjamin R. S. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998 Jun;21(3):317–321. doi: 10.1097/00000421-199806000-00025. [DOI] [PubMed] [Google Scholar]
  64. Patel S. R., Vadhan-Raj S., Papadopolous N., Plager C., Burgess M. A., Hays C., Benjamin R. S. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol. 1997 Jun;15(6):2378–2384. doi: 10.1200/JCO.1997.15.6.2378. [DOI] [PubMed] [Google Scholar]
  65. Pinkerton C. R. Megatherapy for soft tissue sarcomas. EBMT experience. Bone Marrow Transplant. 1991;7 (Suppl 3):120–122. [PubMed] [Google Scholar]
  66. Pisters P. W., Leung D. H., Woodruff J., Shi W., Brennan M. F. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996 May;14(5):1679–1689. doi: 10.1200/JCO.1996.14.5.1679. [DOI] [PubMed] [Google Scholar]
  67. Pollock R. E., Karnell L. H., Menck H. R., Winchester D. P. The National Cancer Data Base report on soft tissue sarcoma. Cancer. 1996 Nov 15;78(10):2247–2257. [PubMed] [Google Scholar]
  68. Presant C. A., Bartolucci A. A., Lowenbraun S. Effects of amphotericin B on combination chemotherapy of metastatic sarcomas. Cancer. 1984 Jan 15;53(2):214–218. doi: 10.1002/1097-0142(19840115)53:2<214::aid-cncr2820530205>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  69. Pronzato P., Losardo P., Pensa F., Tognoni A. High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study. Cancer Chemother Pharmacol. 1998;41(6):513–516. doi: 10.1007/s002800050775. [DOI] [PubMed] [Google Scholar]
  70. Reich S., Overberg-Schmidt U. S., Bührer C., Henze G. Low-dose chemotherapy with vinblastine and methotrexate in childhood desmoid tumors. J Clin Oncol. 1999 Mar;17(3):1086–1086. doi: 10.1200/JCO.1999.17.3.1086. [DOI] [PubMed] [Google Scholar]
  71. Reichardt P., Tilgner J., Hohenberger P., Dörken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998 Apr;16(4):1438–1443. doi: 10.1200/JCO.1998.16.4.1438. [DOI] [PubMed] [Google Scholar]
  72. Reichardt P., Verweij J., Crowther D. Should high-dose chemotherapy be used in the treatment of soft tissue sarcoma? Eur J Cancer. 1997 Aug;33(9):1351–1360. doi: 10.1016/s0959-8049(97)00247-5. [DOI] [PubMed] [Google Scholar]
  73. Rosen G., Forscher C., Lowenbraun S., Eilber F., Eckardt J., Holmes C., Fu Y. S. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994 May 15;73(10):2506–2511. doi: 10.1002/1097-0142(19940515)73:10<2506::aid-cncr2820731009>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  74. Rubin Brian P., Schuetze Scott M., Eary Janet F., Norwood Thomas H., Mirza Sohail, Conrad Ernest U., Bruckner James D. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol. 2002 Sep 1;20(17):3586–3591. doi: 10.1200/JCO.2002.01.027. [DOI] [PubMed] [Google Scholar]
  75. Saeter G., Alvegård T. A., Monge O. R., Strander H., Turesson I., Klepp R., Söderberg M., Wist E., Raabe N., Erlanson M. Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma. A Scandinavian Sarcoma Group Phase II Study. Eur J Cancer. 1997 Sep;33(10):1551–1558. doi: 10.1016/s0959-8049(97)00102-0. [DOI] [PubMed] [Google Scholar]
  76. Santoro A., Tursz T., Mouridsen H., Verweij J., Steward W., Somers R., Buesa J., Casali P., Spooner D., Rankin E. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995 Jul;13(7):1537–1545. doi: 10.1200/JCO.1995.13.7.1537. [DOI] [PubMed] [Google Scholar]
  77. Seiter K., Kemeny N. Successful treatment of a desmoid tumor with doxorubicin. Cancer. 1993 Apr 1;71(7):2242–2244. doi: 10.1002/1097-0142(19930401)71:7<2242::aid-cncr2820710713>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  78. Senderowicz A. M., Headlee D., Stinson S. F., Lush R. M., Kalil N., Villalba L., Hill K., Steinberg S. M., Figg W. D., Tompkins A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998 Sep;16(9):2986–2999. doi: 10.1200/JCO.1998.16.9.2986. [DOI] [PubMed] [Google Scholar]
  79. Serrone L., Zeuli M., Gamucci T., Nardi M., Cognetti F. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. Cancer Chemother Pharmacol. 2001 Mar;47(3):206–210. doi: 10.1007/s002800000219. [DOI] [PubMed] [Google Scholar]
  80. Seymour L., Bramwell V., Moran L. A. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control. 1999 Apr;3(2):145–159. [PubMed] [Google Scholar]
  81. Slater J. D., McNeese M. D., Peters L. J. Radiation therapy for unresectable soft tissue sarcomas. Int J Radiat Oncol Biol Phys. 1986 Oct;12(10):1729–1734. doi: 10.1016/0360-3016(86)90312-3. [DOI] [PubMed] [Google Scholar]
  82. Somerhausen N. de S., Fletcher C. D. Gastrointestinal stromal tumours: an update. Sarcoma. 1998;2(3-4):133–141. doi: 10.1080/13577149877885. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Stadtmauer E. A., O'Neill A., Goldstein L. J., Crilley P. A., Mangan K. F., Ingle J. N., Brodsky I., Martino S., Lazarus H. M., Erban J. K. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000 Apr 13;342(15):1069–1076. doi: 10.1056/NEJM200004133421501. [DOI] [PubMed] [Google Scholar]
  84. Tuveson D. A., Fletcher J. A. Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol. 2001 Jul;13(4):249–255. doi: 10.1097/00001622-200107000-00007. [DOI] [PubMed] [Google Scholar]
  85. Van Glabbeke M., van Oosterom A. T., Oosterhuis J. W., Mouridsen H., Crowther D., Somers R., Verweij J., Santoro A., Buesa J., Tursz T. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999 Jan;17(1):150–157. doi: 10.1200/JCO.1999.17.1.150. [DOI] [PubMed] [Google Scholar]
  86. Weingrad D. N., Rosenberg S. A. Early lymphatic spread of osteogenic and soft-tissue sarcomas. Surgery. 1978 Aug;84(2):231–240. [PubMed] [Google Scholar]
  87. Weiss A. J., Lackman R. D. Low-dose chemotherapy of desmoid tumors. Cancer. 1989 Sep 15;64(6):1192–1194. doi: 10.1002/1097-0142(19890915)64:6<1192::aid-cncr2820640605>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  88. Wiklund T., Saeter G., Strander H., Alvegård T., Blomqvist C. The outcome of advanced soft tissue sarcoma patients with complete tumour regression after either chemotherapy alone or chemotherapy plus surgery. The Scandinavian Sarcoma Group experience. Eur J Cancer. 1997 Mar;33(3):357–361. doi: 10.1016/s0959-8049(97)89006-5. [DOI] [PubMed] [Google Scholar]
  89. van Oosterom A. T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., Martens M., Webb A., Sciot R., Van Glabbeke M. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001 Oct 27;358(9291):1421–1423. doi: 10.1016/s0140-6736(01)06535-7. [DOI] [PubMed] [Google Scholar]
  90. van Oosterom A. T., Mouridsen H. T., Nielsen O. S., Dombernowsky P., Krzemieniecki K., Judson I., Svancarova L., Spooner D., Hermans C., Van Glabbeke M. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer. 2002 Dec;38(18):2397–2406. doi: 10.1016/s0959-8049(02)00491-4. [DOI] [PubMed] [Google Scholar]

Articles from Sarcoma are provided here courtesy of Wiley

RESOURCES